Advaxis Incorporated (OTCBB: ADXS) has provided a complete response to the FDAs questions regarding the proposed use in humans of Lovaxin C, a live Listeria vaccine directed against HPV induced disease, in the treatment of CIN.

Advaxis Incorporated (OTCBB: ADXS), a developmental biotechnology company, and a team of investigators from the University of Pennsylvania and the Hilman Cancer Center in Pittsburgh recently published a research paper in the October 2008 edition of Cancer Research demonstrating the tumor eliminating properties of a live Listeria monocytogenes (Lm) vaccine in a variety of different of cancer types in a mouse model.

Advaxis Incorporated (OTCBB: ADXS) Chairman and CEO Tom Moore will present at this year's World Vaccine Congress 2008, being hosted at Le Palais des Congres de Lyon in Lyon, France. The Conference will be held October 6 - 9, 2008. Mr.

The Board of Directors of Advaxis Inc., (OTCBB: ADXS), a developmental biotechnology company, has approved, by majority vote, the motion to accept a senior promissory note (the "Note") from Advaxis Chairman & CEO Thomas Moore.

Advaxis Inc., (OTCBB: ADXS), a developmental biotechnology company, received comments from the U. S.